Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies vaccines (human diploid cell, freeze-dried) for human use; haemophilus influenzae type b conjugate vaccines; measles and rubella combined vaccines (live); SARS-CoV-2 vaccines (vero cell, inactivated); and COVID-19 vaccines (ChAdOx1-S recombinant). It also develops measles, mumps, and rubella vaccines; DTaP-Hib-IPV combined vaccines, 4-valent influenza (split) vaccines, and poliomyelitis vaccines (vero cells, inactivated for the Sabin strain). In addition, the company engages in general and special freight transportation; warehousing services; technology development; import and export of goods and technology; agency import and export; investment in and establishment of pharmaceutical projects and other industries; pharmaceutical technology development, information consulting, and leasing services for self-owned buildings and equipment; wholesale and trade of preventive biological products; technical services; technical consulting and exchange; technology transfer and promotion; and contract manufacturing of pharmaceutical products. It exports its products. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
